1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow PF-06863135: new trials by email Literature Review of PF-06863135 trials Research Report on PF-06863135
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. Elranatamab - Elranatamab, Myeloma | Phase 2 | Completed | Pfizer | 39 | 2021-12-21 | 2026-09-29 |
Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Vascular Diseases (1)
Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
Pfizer (1)
China (1)